Clearmind Medicine adds Tel Aviv Sourasky Medical Center to ongoing AUD trial

Clearmind Medicine (CMND) announced the addition of Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, as an additional clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder. This expansion follows the recent enrollment of the first patient in the trial, announced on June 5, 2025, marking a significant milestone in the development of CMND-100. The study at Tel Aviv Sourasky Medical Centerwill be led by Dr. David Zeltser, Director of the Emergency Medicine Department. Tel Aviv Sourasky Medical Center joins other prestigious institutions participating in the trial, including Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine in the United States. The inclusion of Tel Aviv Sourasky Medical Center further strengthens Clearmind’s clinical network, enhancing the trial’s capacity to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also exploring its potential to reduce alcohol cravings and consumption in patients with AUD.